INKT - NASDAQ
MiNK Therapeutics, Inc.
$12.76
+1.4%MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
At a Glance
Live SnapshotMiNK Therapeutics, Inc. Profit Bridge
Profitability Analysis
MiNK Therapeutics, Inc. Income Statement
INKT • NASDAQ
| MiNK Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 689.6K | |
GROSS PROFIT | |||||||
(181.7K) | (215.4K) | (204.6K) | (121.7K) | (78K) | (55.1K) | (0.0) | |
-181.7K | -215.4K | -204.6K | -121.7K | -78K | -55.1K | 689.6K | |
OPERATING INCOME | |||||||
(12.3M) | (10.4M) | (22.7M) | (30.8M) | (18.5M) | (10.7M) | (23.5M) | |
(6.7B) | (4.1M) | (7.4M) | (7.7M) | (4.6M) | (1.2M) | (3.8M) | |
(5.8B) | (6.3M) | (15.5M) | (23.1M) | (14M) | (9.5M) | (19.7M) | |
-12.5M | -10.7M | -22.9M | -30.9M | -18.6M | -10.8M | -22.3M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (253.3K) | (2.4M) | (2.4M) | (1.6M) | |
180.2K | 172.6K | 463.3K | 0.0 | -2.4M | -2.4M | -1.6M | |
-12.5B | (0.0) | -204.6K | (0.0) | (0.0) | (0.0) | (0.0) | |
-7K | -134.6K | 463.2K | 3M | -11.6M | -5.4M | -1.5M | |
-12.5M | -10.8M | -22.5M | -28M | -30.2M | -16.2M | -23.8M | |
NET INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2.1M) | |
-12.5M | -10.8M | -22.5M | -28M | -30.2M | -16.2M | -23.8M |
SEC Filings
INKT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 13, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 29, 2025 | 2025 | |
S-3/A S-3/A (Amended) N/A | December 10, 2025 | December 10, 2025 | ||
8-K 8-K 2025 N/A | December 08, 2025 | November 14, 2025 | 2025 |
Related Guides
Continue your INKT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.